首页> 美国卫生研究院文献>Annals of Translational Medicine >Efficacy and safety of Shen-Yuan-Dan capsules for peri-procedural myocardial injury following percutaneous coronary intervention: study protocol for a randomized double-blind placebo-controlled trial
【2h】

Efficacy and safety of Shen-Yuan-Dan capsules for peri-procedural myocardial injury following percutaneous coronary intervention: study protocol for a randomized double-blind placebo-controlled trial

机译:申元丹胶囊在经皮冠状动脉介入治疗后对围手术期心肌损伤的疗效和安全性:一项随机双盲安慰剂对照试验的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundPeri-procedural myocardial injury (PMI) during percutaneous coronary intervention (PCI) will result in an unfavorable clinical prognosis in patients, thus urgently necessitating effective drug treatment measures. Shen-Yuan-Dan (SYD) capsules are a traditional Chinese medicine (TCM) preparation that have been found to have potential myocardial protection effects during the peri-procedural phase of PCI in previous clinical and basic research; however, there is a lack of rigorous, randomized, and controlled studies. The aim of this study is to evaluate the efficacy and safety of SYD in decreasing PMI.
机译:背景技术经皮冠状动脉介入治疗(PCI)时的过程性心肌损伤(PMI)将导致患者的临床预后不良,因此迫切需要采取有效的药物治疗措施。申元丹(SYD)胶囊是中药(TCM)制剂,在先前的临床和基础研究中已发现在PCI围手术期阶段具有潜在的心肌保护作用。但是,缺乏严格,随机和对照的研究。这项研究的目的是评估SYD在降低PMI中的疗效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号